NCT00101569
Completed
Phase 3
Aripiprazole Oral Acceptability Trial
Otsuka Pharmaceutical Development & Commercialization, Inc.1 site in 1 country59 target enrollmentMarch 2004
Overview
- Phase
- Phase 3
- Intervention
- Aripiprazole
- Conditions
- Schizophrenia
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Enrollment
- 59
- Locations
- 1
- Primary Endpoint
- acceptability
- Status
- Completed
- Last Updated
- 12 years ago
Overview
Brief Summary
The purpose of this trial is to study liquid aripiprazole in patients with stable schizophrenia.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Stable patients currently receiving aripiprazole or other antipsychotic medications.
Exclusion Criteria
- Not provided
Arms & Interventions
A1
Intervention: Aripiprazole
A2
Intervention: Aripiprazole
Outcomes
Primary Outcomes
acceptability
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Safety and Tolerability Trial of Aripiprazole IM Depot Treatment in Adult Subjects With Schizophrenia Stabilized on Oral Antipsychotics Other Than AripiprazoleSchizophreniaNCT01552772Otsuka Pharmaceutical Development & Commercialization, Inc.60
Completed
Phase 4
Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social AnxietySchizophreniaSchizoaffective DisorderSocial Anxiety DisorderNCT00177008University of Medicine and Dentistry of New Jersey18
Completed
Phase 3
Aripiprazole in Adolescents With SchizophreniaSchizophreniaNCT00102063Otsuka Pharmaceutical Development & Commercialization, Inc.302
Completed
Phase 3
Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical TrialsSchizophreniaNCT00239356Otsuka Pharmaceutical Development & Commercialization, Inc.119
Terminated
Phase 4
Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in SchizophreniaSchizophreniaNCT00712270Kettering Health Network21